The University of Missouri has launched a groundbreaking clinical trial in cancer care, utilizing a novel radiopharmaceutical therapy produced at its research reactor. This initiative, undertaken by the School of Medicine and MU Health Care, exemplifies the institution’s capability to transition cutting-edge treatments from research to clinical trials.
In collaboration with ABK Biomedical, the university’s cancer researchers have commenced patient enrollment at the Ellis Fischel Cancer Center, employing Eye90 microspheres since February 9. This trial signifies a pivotal advancement as the university expands its radiopharmaceutical clinical trial capabilities in partnership with the NextGen Precision Health initiative.
“The significance of this trial lies in showcasing our campus’s research strength,” stated Mun Choi, President of the University of Missouri. “Our extensive facilities allow us to partner with industry, develop, and test innovative treatments, accelerating their delivery to patients.”
Eye90 microspheres are radiopaque glass beads with yttrium-90, targeting unresectable liver tumors such as hepatocellular carcinoma and metastatic colorectal cancer. The University of Missouri Research Reactor (MURR) is the sole domestic supplier of Y-90, producing these microspheres for ABK Biomedical.
“This marks our first radiopharmaceutical clinical trial at Ellis Fischel,” noted Ryan Davis, associate professor of clinical radiology. “Such studies provide early therapy access for our patients and reinforce our leadership in translational research. We are eager to contribute to this study, recognizing the growing importance of targeted radiotherapy.”
Eye90’s design facilitates precise delivery visualization, enabling accurate targeting of liver tumors while minimizing radiation exposure to healthy tissue. “Collaborations with ABK Biomedical enhance cancer patient care locally and globally,” remarked Matt Sanford, MURR’s executive director. “Our radioisotope production expertise supports transforming laboratory innovations into clinical applications, offering new hope for patients.”
Mizzou has pioneered glass microsphere development for Y-90 therapy since the 1980s, with the first treatment, TheraSphere, receiving FDA approval in 2021. MURR remains the exclusive U.S. producer. ABK Biomedical’s collaboration with MURR ensures consistent dose provision for trials, with Mizzou researchers validating Eye90’s effectiveness and safety.
Jeffrey Bryan, professor of oncology, led initial animal model studies, later conducting a clinical trial in dogs with hepatocellular carcinoma. The research demonstrated treatment efficacy and safety, with imaging conducted at the MU Veterinary Health Center.
The clinical trial aims to assess Eye90 microspheres’ safety and effectiveness for unresectable liver tumors, involving a single administration followed by a year-long monitoring period. ABK Biomedical’s ongoing studies, including those at Auckland Hospital, seek comprehensive data for regulatory approval and broader adoption.
The University of Missouri and Ellis Fischel remain dedicated to advancing treatment options and enhancing patient care through innovative research and collaboration.
